Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol

Veterinary Journal

Volumn 188, Issue 3, 2011, Pages 346-351

  Torres, Marta ^a   Bardagí, Mar ^a   Roura, Xavier ^a   Zanna, Giordana ^a   Ravera, Iván ^a   Ferrer, Lluís ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Allopurinol; Canine; Follow up; Leishmaniosis; Meglumine antimoniate

Indexed keywords

ALLOPURINOL; MEGLUMINE ANTIMONATE; PROTOZOON ANTIBODY; XANTHINE;

ANTIBODY TITER; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DOG; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLOW UP; HYDRONEPHROSIS; IMMUNOGLOBULIN BLOOD LEVEL; LEISHMANIASIS; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NONHUMAN; PARASITEMIA; PROTEIN BLOOD LEVEL; RELAPSE; RETROSPECTIVE STUDY; UROLITHIASIS; UVEITIS; VASCULITIS;

ALLOPURINOL; ANIMALS; ANTIPROTOZOAL AGENTS; DOG DISEASES; DOGS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; LEISHMANIASIS; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

CANIS FAMILIARIS;

EID: 79955792633     PISSN: 10900233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tvjl.2010.05.025     Document Type: Article

References (25)

1. Alvar J., Cañavate C., Molina R., Moreno J., Nieto J. Canine leishmaniasis. Advances in Parasitology 2004, 57:1-88.
2. Baneth G., Shaw S. Chemotherapy of canine leishmaniosis. Veterinary Parasitology 2002, 106:315-324.
3. Carrillo E., Moreno J. Cytokine profiles in canine visceral leishmaniasis. Veterinary Immunology and Immunopathology 2009, 128:67-70.
4. Cavaliero T., Arnold P., Mathis A., Glaus T., Hoffman-Lehmann R., Deplazes P. Clinical serologic, and parasitologic follow-up after long-term allopurinol therapy of dogs naturally infected with Leishmania infantum. Journal of Veterinary Internal Medicine 1999, 13:330-334.
5. Denerolle P., Bourdoiseau G. Combination allopurinol and antimony treatment versus antimony alone and allopurinol alone in the treatment of canine leishmaniasis (96 cases). Journal of Veterinary Internal Medicine 1999, 13:413-415.
6. Francino O., Altet L., Sánchez-Robert E., Rodríguez A., Solano-Gallego L., Alberola J., Ferrer L., Sánchez A., Roura X. Advantages of real-time PCR assay for diagnosis and monitoring of canine leishmaniosis. Veterinary Parasitology 2006, 137:214-221.
7. Ginel P.J., Lucena R., López R., Molleda J.M. Use of allopurinol for maintenance of remission in dogs with leishmaniasis. Journal of Small Animal Practice 1998, 39:271-274.
8. Koutinas A.F., Saridomichelakis M.N., Mylonakis M.E., Leontides L., Polizopoulou Z., Billinis C., Argyriadis D., Diakou N., Papadopoulos O. A randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniosis. Veterinary Parasitology 2001, 98:247-261.
9. Manna L., Reale S., Vitale F., Caracappa S., Pavone L.M., Della Morte R., Cringoli G., Staiano N., Gravino A.E. Comparison of different tissue sampling for PCR-based diagnosis and follow-up of canine visceral leishmaniosis. Veterinary Parasitology 2004, 125:251-262.
10. Manna L., Gravino A.E., Picillo E., Decaro N., Buonavoglia C. Leishmania DNA quantification by real-time PCR in naturally infected dogs treated with miltefosine. Annals of the New York Academy of Sciences 2008, 1149:358-360.
11. Manna L., Reale S., Vitale F., Picillo E., Pavone L.M., Gravino A.E. Real-time PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinol. The Veterinary Journal 2008, 177:279-282.
12. Manna L., Reale S., Vitale F., Gravino A.E. Evidence for a relationship between Leishmania load and clinical manifestations. Research in Veterinary Science 2009, 87:76-78.
13. Manna L., Vitale F., Reale S., Picillo E., Neglia G., Vescio F., Gravino A.E. Study of the efficacy of miltefosine and allopurinol in dogs with leishmaniosis. The Veterinary Journal 2009, 182:441-445.
14. Miró G., Oliva G., Cruz I., Cañavate C., Mortarino M., Vischer C., Bianciardi P. Multicentric controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis. Veterinary Dermatology 2009, 20:397-404.
15. Moreno J., Nieto J., Chamizo C., González F., Blanco F., Barker D.C., Alvar J. The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy. Veterinary and Immunology and Immunopathology 1999, 30:181-195.
16. Muñiz-Junqueira M.I., de Paula-Coelho V.N. Meglumine antimoniate directly increases phagocytosis, superoxide anion and TNF-production, but only via TNF - it indirectly increases nitric oxide production by phagocytes of healthy individuals, in Vitro. International Immunopharmacology 2008, 8:1633-1638.
17. Noli C., Auxilia S. Treatment of Old World visceral leishmaniasis: a systematic review. Veterinary Dermatology 2005, 16:213-232.
18. Pennisi M.G., Reale S., Lo Giudice S., Masucci M., Caracappa S., Vitale M., Vitale F. Real-time PCR in dogs treated for leishmaniosis with allopurinol. Veterinary Research Communications 2005, 20(Suppl.):301-303.
19. Plevraki K., Koutinas A.F., Kaldrymidou H., Roumpies N., Papazoglou L.G., Saridomichelakis M.N., Savvas I., Leondides L. Effects of allopurinol treatment on the progression of chronic nephritis in canine leishmaniosis (Leishmania infantum). Journal of Veterinary Internal Medicine 2006, 20:228-233.
20. Rhalem A., Sahibi H., Lasri S., Jaffe C. Analysis of immune responses in dogs with canine visceral leishmaniasis before, and after, drug treatment. Veterinary Immunology and Immunopathology 1999, 71:69-76.
21. Roura X., Sánchez A., Ferrer L. Diagnosis of canine leishmaniasis by a polymerase chain reaction technique. The Veterinary Record 1999, 144:262-264.
22. Shaw S., Langton D.A., Hillman T.J. Canine leishmaniosis in the United Kingdom: a zoonotic disease waiting for a vector?. Veterinary Parasitology 2009, 163:281-285.
23. Slappendel R.J., Teske E. The effect of intravenous or subcutaneous administration of meglumine antimoniate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial. Veterinary Quarterly 1997, 19:10-13.
24. Solano-Gallego L., Llull J., Ramis A., Fernández-Bellón H., Rodríguez A., Ferrer L., Alberola J. Longitudinal study of dogs living in an area of Spain highly endemic for leishmaniasis by serologic analysis and the leishmanin skin test. American Journal of Tropical Medicine and Hygiene 2005, 72:815-818.
25. Solano-Gallego L., Koutinas A., Miró G., Cardoso L., Pennisi M.G., Ferrer L., Bourdeau P., Oliva G., Baneth G. Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. Veterinary Parasitology 2009, 165:1-18.